Gillette India Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹24,950 Cr
- Book Value
- ₹290
- Stock P/E
- 37.4
- Dividend Yield
- 2.35%
- ROE
- 66.4%
- ROCE
- 90.6%
- PEG Ratio
- 1.61
- EV/EBITDA
- 25.0
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Gillette India share price today
Gillette India (NSE: GILLETTE) runs the razor-and-blades model in its original home: the razor. Blades are the annuity — bought monthly, branded by father-to-son habit, distributed to every kirana — and Oral-B toothbrushes add a second duopoly-grade franchise. The financials are among the most extraordinary on the exchange: 90.6% ROCE, 66.4% ROE, zero debt, 30.3% operating margins, and a 2.35% dividend from a business that needs almost no capital to grow.
Our internal note calls it P&G’s most quietly wonderful Indian listing. At 37.4×, the universe tag is wait — wonderful is known; the multiple says so.
The subscription nobody cancels
Blade refills are consumable, habitual and brand-locked — the closest physical equivalent to subscription software, with 23.2% five-year profit CAGR as premiumisation (multi-blade systems, skin-care adjacency) lifts realisations. Oral-B rides oral-care penetration, still low across Bharat. P&G’s playbook — advertising scale, distribution muscle, relentless premiumisation — executes through a listed entity with 75% parent holding and MNC governance.
Watch-items: male-grooming disruption (D2C razor brands nibble globally; India’s kirana moat has held), input (steel/polymer) costs, parent royalty terms, and the low-single-digit volume growth that premiumisation must keep outrunning.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹24,950 Cr |
| P/E (TTM) | 37.4 |
| EV/EBITDA | 25.0 |
| Operating margin | 30.3% |
| ROE / ROCE | 66.4% / 90.6% |
| Debt to equity | 0.00 |
| Sales CAGR (5y) | 13.0% |
| Profit CAGR (5y) | 23.2% |
| Promoter holding | 75.0% |
| EPS (TTM) | ₹205.1 |
Gillette India share price target 2026 to 2030
EPS base ₹205.1 (TTM). Bear: volume stagnation meets D2C nibbling — 7% growth, multiple at 26×. Base: premiumisation compounds steadily — 12% growth at 33×. Bull: grooming and oral-care penetration accelerate — 16% growth at 41×.
| Year | Bear (26×, +7%) | Base (33×, +12%) | Bull (41×, +16%) |
|---|---|---|---|
| 2026 | ₹5,705 | ₹7,580 | ₹9,755 |
| 2027 | ₹6,105 | ₹8,490 | ₹11,315 |
| 2028 | ₹6,535 | ₹9,510 | ₹13,125 |
| 2029 | ₹6,990 | ₹10,650 | ₹15,225 |
| 2030 | ₹7,480 | ₹11,930 | ₹17,660 |
From ₹7,662, the base case is ≈ +56% over four and a half years plus the 2.35% yield; the bear is −2%. Ninety-percent-ROCE franchises don’t crash; they occasionally pause — the range below is priced for the pauses.
Reasons to own Gillette India (at the right price)
- The razor-blade annuity — habitual, branded, consumable forever.
- 90% ROCE: the highest-grade capital efficiency P&G owns in India.
- A 2.35% yield fully funded by a capital-light model.
- Oral-B is a second duopoly franchise riding penetration, not share wars.
- Premiumisation has decades of headroom in male grooming.
The risks: volume growth is structurally slow, D2C razor insurgents test the moat’s edges, and 37× already curtsies to the quality.
Should you buy at the current price?
The live buy range below is for members — where wonderful meets worthwhile.
FAQ
What is the Gillette India share price target for 2030? Base case ≈ ₹11,930 (33× on 12% compounded growth), bear ≈ ₹7,480, bull ≈ ₹17,660. Arithmetic above.
How is 90% ROCE even possible? Almost no capital: brands are amortised history, manufacturing is compact, distribution is P&G’s shared muscle. Profits divided by a tiny capital base produce arithmetic like this.
Are D2C razor brands a real threat in India? They’ve taken urban online niches; the kirana-distributed refill economy — where most blades sell — has proven far stickier than Western markets’ subscription disruption.
When are Gillette India’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.